Monitoring anticoagulation by fondaparinux: Determination of anti factor Xa-levels;Überwachung der antikoagulanzientherapie mit fondaparinux: Bestimmung der anti-faktor-Xa-spiegel

Hamostaseologie

Volumn 25, Issue 3, 2005, Pages 281-285

  Damgen Von Brevern G ^a   Klaffling C ^a   Lindhoff Last, Edelgard ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Anti factor Xa level; Chromogenic substrate assay; Fondaparinux

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHROMOGENIC SUBSTRATE; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; POLYSACCHARIDE;

ANTICOAGULANT THERAPY; BLEEDING; DRUG MONITORING; HEMATOLOGICAL PARAMETERS; HUMAN; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; ARTICLE; BIOAVAILABILITY; DRUG ANTAGONISM; METABOLISM;

ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; DRUG MONITORING; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES;

EID: 23944461120     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619662     Document Type: Review

References (20)

1. Amiral J, Lormeau JC, Marfing-Koka A et al. Absence of cross-reactivity of SR 90107A/ORG 31540 pentasaccharid with antibodies to heparin PF 4 complexes developed in heparin-induced thrombozytopenia. Blood Coag Fibrinol 1997; 8: 114-7.
2. Bauer KA, Erikkson BI, Lassen MR et al. Fondaparinux compared with Enoxaparin for the prevention of venous thrombembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
3. Boneu B, Necciari J, Cariou R et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107/ORG-31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
4. Depasse F, Gerotziafas GT, Busson J, et al. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost 2004; 2: 346-8.
5. Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 (Suppl 2): 1-9.
6. Eriksson BI, Bauer KA, Lassen MR et al. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
7. Harenberg J, Jörg I., Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89: 1017-8.
8. Heinzelmann M, Bosshart H. Fondaparinux sodium lacks immunmodulatory effects of heparin. Am J Surg 2004, 187: 111-3.
9. Herbert JM, Petitou M, Lormeau JC et al. SR 90107 A/Org 31540, a novel anti factor Xa anti-thrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26.
10. Kirchmayr K, Piechottka G, Kläffling C et al. Development of two chromogenic substrate methods for monitoring of Fondaparinux sodium, a new selective inhibitor of factor Xa. Hämostaseologie 2004; 24: A8(V9).
11. Lassen MR. The EHPHESUS study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism after elective hip replacement surgery. Thromb Haemost 2001; (Suppl): OC45.
12. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to AT.mediated neutralization of Factor Xa. Thromb Haemost 1995; 74: 1474-7.
13. Matisse Investigators. Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism. N Eng J Med 2003; 349: 1695-702.
14. Matziolis G, Perka C, Disch A et al. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 2003; 73: 370-9.
15. Paolucci F, Frasa H, van Aarle F et al. Two sensitive and rapid chromogenic assays of fondaparinux Sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 2003; 49: 451-60.
16. Petitou M, Duchaussoy P, Ledermann I et al. Synthesis of heparin fragments. A chemical synthesis of the pentasachcharide O-(2-deoxy-2-sulfamido- 6-O-sulfo-alpha-D-glucopyranosyl)-1à4)-O-(beta-D-glucopyranosyluronic acid)-(1à4)-0-(2-deoxy-2-sulfamido-3, 6-di-O-sulfo-alpha-D- glucopyranosyl)-1à4)-O-(2-O- sulpho-alpha-L-idopyrano-syluronic acid)-(1à4)-2-deoxy-2sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr Res 1986; 147: 221-36.
17. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. Circulation 2000; 102: 2726-31.
18. Turpie AGG, Bauer KA, Eriksson BI et al. Superiority of fondaparinux over enoxaparin in preventing venous thrombembolism in major orthopedic surgery using different efficacy end points. Chest 2004; 126: 501-8.
19. Walenga JM, Fareed J, Jeske WP et al. Development of a synthetic heparin pentasaccharide: Fondaparinux. Turk. J Haematol 2002; 19: 137-50.
20. Walenga JM, Hoppensteadt D, Mayuga M et al. Functionality of pentasaccharide depends on endogenous antithrombin levels. Blood 2000; 96: 817.